Literature DB >> 546893

Determination of bromocriptine in plasma: comparison of gas chromatography, mass fragmentography and liquid chromatography.

N E Larsen, R Ohman, M Larsson, E F Hvidberg.   

Abstract

Gas chromatographic, mass fragmentographic and liquid chromatographic techniques for the determinations of bromocriptine (2-bromo-alpha-ergocriptine; Parlodel) in human plasma are described. These methods were found to be suitable for determining concentrations of bromocriptine down to 0.5, 1.0 and 10.0 microgram/l, respectively. Accuracy, specificity and analytical capacity were satisfactory for all three methods. Gas chromatography was compared with liquid chromatography, and the two methods were demonstrated to give identical results in patients treated with bromocriptine for Parkinson's disease. Gas chromatography was also compared with mass fragmentography, and the results from these two assays were also in agreement.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 546893     DOI: 10.1016/s0021-9673(00)86007-0

Source DB:  PubMed          Journal:  J Chromatogr


  4 in total

1.  Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics.

Authors:  Johnique Billups; Cynthia Jones; Tanise L Jackson; Seth Y Ablordeppey; Shawn D Spencer
Journal:  Biomed Chromatogr       Date:  2010-07       Impact factor: 1.902

2.  Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.

Authors:  G Maurer; E Schreier; S Delaborde; R Nufer; A P Shukla
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

3.  Bromocriptine concentration in saliva plasma after long-term treatment of patients with Parkinson's disease.

Authors:  M L Friis; T Johnsen; N E Larsen; E F Hvidberg; H Pakkenberg
Journal:  Eur J Clin Pharmacol       Date:  1980-08       Impact factor: 2.953

4.  Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease.

Authors:  M L Friis; U Grøn; N E Larsen; H Pakkenberg; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.